Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + Nivolumab + Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma
NCT04413123Phase 2Active, not recruiting
- Start
- Nov 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in non-clear cell renal cell carcinoma (nccRCC). Started Nov 2020; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT04413123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04413123.